Generation Bio stock deal closes at USD 4.2913 per share
Published on 09/25/2026 at 07:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Generation Bio stock deal closes at USD 4.2913 per share after XOMA Royalty completed its acquisition of the biotechnology company on February 9, 2026. Each Generation Bio share was exchanged for cash and one non-tradeable contingent value right, or CVR, according to StockTitan.
Cash payment sets the floor
The cash component was USD 4.2913 per share. The same filing states that the CVR could deliver estimated maximum contingent consideration of USD 25.01 per unit, subject to the agreement terms and future outcomes.
The consideration structure separates the immediate payment from the potential value of Generation Bio's remaining assets. That distinction matters because the USD 4.2913 payment was fixed at closing, while the CVR depends on specified conditions rather than a regular market quotation.
Ownership changed in February
XOMA Royalty's tender offer received 4,722,533 validly tendered shares, according to StockTitan. A follow-on merger then converted the remaining shares into the same USD 4.2913 cash and one-CVR package.
The corporate status is now different from the earlier public-market setup. Generation Bio continues as the surviving corporation, but it became a wholly owned subsidiary of XOMA Royalty after the merger, according to StockTitan.
Nasdaq exit changes the reference point
The transaction filing also said Generation Bio requested delisting from Nasdaq and planned to terminate its SEC reporting obligations. As of September 25, 2026, the key reference for the former listed company is therefore the February cash-and-CVR merger consideration, not a continuing exchange price.
The deal's headline value is clear: USD 4.2913 in cash per share, plus one CVR with an estimated maximum of USD 25.01. The two components have different certainty and timing, so they should not be treated as one guaranteed cash amount.
Generation Bio key facts
- Company: Generation Bio Co.
- Ticker: GBIO
- Sector / Industry: Biotechnology
- Acquisition status: Wholly owned subsidiary of XOMA Royalty
- Merger date: February 9, 2026
- Cash consideration: USD 4.2913 per share
- CVR consideration: One non-tradeable CVR per share
